All Publications

Export 160 results:
Author Title Type [ Year(Asc)]
2013
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. Santoro M, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G et al. HIV Med, 2013 Oct, Volume 14, Issue 9, p.571-7, (2013)
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. Dolling D, Dunn D, Sutherland K, Pillay D, Mbisa J, Parry C, Post F, Sabin C and Cane P. J Antimicrob Chemother, 2013 Oct, Volume 68, Issue 10, p.2339-43, (2013)
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Mocroft A, Furrer H, Miro J, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D et al. Clin Infect Dis, 2013 Oct, Volume 57, Issue 7, p.1038-47, (2013)
Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. Costagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, De Luca A, Jansen K et al. J Infect Dis, 2013 Mar 01, Volume 207, Issue 5, p.759-67, (2013)
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. Winston A, Jose S, Gibbons S, Back D, Stöhr W, Post F, Fisher M, Gazzard B, Nelson M, Gilson R et al. J Antimicrob Chemother, 2013 Jun, Volume 68, Issue 6, p.1354-9, (2013)
Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care. Huntington S, Thorne C, Bansi L, Anderson J, Newell M, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. AIDS, 2013 Jan 02, Volume 27, Issue 1, p.95-103, (2013)
HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. Dolling D, Dunn D, Geretti A and Sabin C. Clin Infect Dis, 2013 Jan, Volume 56, Issue 1, p.162-3, (2013)
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A, Codoñer F, Van Laethem K et al. J Infect Dis, 2013 Apr 15, Volume 207, Issue 8, p.1216-20, (2013)
Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D and Phillips A. Antivir Ther, 2013, Volume 18, Issue 2, p.213-9, (2013)
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). Mocroft A, Lundgren J, Sabin M, Monforte A, Brockmeyer N, Casabona J, Castagna A, Costagliola D, Dabis F, De Wit S et al. PLoS Med, 2013, Volume 10, Issue 9, p.e1001510, (2013)
The impact of age on associations between HIV-disease markers (immunological and virological) and systemic markers of metabolic function in therapy-naïve HIV-infected subjects in the UK Collaborative HIV Cohort (CHIC) Samuel M, Jose S, Winston A and Sabin C. 19th Annual Conference of the British HIV Association (BHIVA), 2013, Volume HIV Medicine 2013; 14 (Suppl. 2), 12-77, p.Poster 82, (2013)
HLA B*5701 positivity, disease status and response to combination antiretroviral therapy (cART) in the UK Collaborative HIV Cohort (CHIC) study Jose S, Sabin C, Leen C, Chadwick D and for the UK CHIC Study. 19th Annual Conference of the British HIV Association (BHIVA), 2013, Volume HIV Medicine 2013; 14 (Suppl. 2), 12-77, p.Poster 144, (2013)
Failure to achieve an adequate CD4 count response despite regular engagement in HIV care and consistent viral suppression O'Connor J, Smith C, Lampe F, Johnson M, Sabin C and Phillips A. 19th Annual Conference of the British HIV Association (BHIVA), 2013. Poster 46, Volume HIV Medicine 2013; 14 (Suppl. 2), 12-77, p.Poster 46, (2013)
Rapid Increase in the Frequency of Wild Type HIV-1 Drug Resistance Reports among ART-experienced Patients: UK Dolling D, Nelson M, Schwenk A, Churchill D, Pillay D, Dunn D and UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study. 20th Conference on Retroviruses and Opportunistic Infections, 2013, (2013)
2012
Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C and Post F. Am J Kidney Dis, 2012 Oct, Volume 60, Issue 4, p.539-47, (2012)
Biomarkers to monitor safety in people on art and risk of mortality. Bansi L, Gazzard B, Post F, Phillips A, Johnson M, Hill T, Gilson R, Leen C, Walsh J, Fisher M et al. J Acquir Immune Defic Syndr, 2012 May 01, Volume 60, Issue 1, p.51-8, (2012)
Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. Dolling D, Phillips A, Delpech V, Pillay D, Cane P, Crook A, Shepherd J, Fearnhill E, Hill T and Dunn D. HIV Med, 2012 May, Volume 13, Issue 5, p.309-14, (2012)
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A et al. J Acquir Immune Defic Syndr, 2012 Mar 01, Volume 59, Issue 3, p.294-9, (2012)
Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C and Post F. Nephrol Dial Transplant, 2012 Jun, Volume 27, Issue 6, p.2291-7, (2012)
Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women. Huntington S, Bansi L, Thorne C, Anderson J, Newell M, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. BMC Med Res Methodol, 2012 Jul 28, Volume 12, p.110, (2012)
Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK. Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A, Dunn D, Gazzard B et al. HIV Med, 2012 Jan, Volume 13, Issue 1, p.73-8, (2012)
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy? Gompels M, Dunn D, Phillips A, Dooley D, Thomas A, Anderson J, Post F, Pillay D, Gazzard B, Hill T et al. J Infect Dis, 2012 Feb 15, Volume 205, Issue 4, p.540-7, (2012)
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Costagliola D, Lodwick R, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, De Luca A et al. Lancet Infect Dis, 2012 Feb, Volume 12, Issue 2, p.119-27, (2012)
Uptake and outcome of combination antiretroviral therapy in men who have sex with men according to ethnic group: the UK CHIC Study. . J Acquir Immune Defic Syndr, 2012 Apr 15, Volume 59, Issue 5, p.523-9, (2012)
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. Barber T, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D and Dunn D. J Antimicrob Chemother, 2012 Apr, Volume 67, Issue 4, p.995-1000, (2012)